Citadel Securities knows what’s up. It’s the designated market maker on the NYSE and, per the company, represents about 62% of listings on the exchange. And it’s seeing something it hasn’t seen in years.

“Echoing our colleagues in institutional derivatives this morning, the current level of retail bullishness is something to keep a close eye on,” Citadel Securities’ Thomas Sozzi wrote. “In cash equity space, retail clients on our platform have been net buyers for the past 18 trading sessions in a row! This bullish streak hasn’t been seen on our platform in over 3 years.”

Things are getting wild out there. Again, take Opendoor for example. The options flows were still overwhelmingly tilted toward calls — calls outnumbered puts by about 1.9:1 Tuesday versus roughly 2:1 on Monday — but the most active option traded on Opendoor was a put with a strike price of $2.50 that expires on Friday. When flows are more of the story than fundamentals, it’s this relatively boring tallying of motivated buying versus motivating selling that can give a clue as to how much momentum a move has and whether it’s at risk of reversing.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions. Citadel Securities has a business relationship with Robinhood.)

While this company’s stock trades on the Nasdaq (ticker: HSCS), you won’t find this offering there.

HeartSciences is a leader in AI technology that makes heart disease easier to detect on the frontlines. 

Their cloud-based software platform is designed for use with existing ECG devices without the need for new hardware — which could have applications for the 300 million ECGs performed globally every year.  

Shares of HSCS common stock have closed as high as $5.73 this month and its closing price on 7/21 was $4.03.¹

But through their special unit offering, you can get a share of unlisted preferred stock for $3.50 — which can be converted into a share of Nasdaq-traded stock at any time — plus a warrant.²

HeartSciences is also targeting FDA submission this summer,³ making now a key moment to invest. 

Invest in HeartSciences unit offering now at $3.50/unit price.⁴

¹ 52-week range for HSCS is $2.36 to $6.47 as of 7/21/25.

It’s not just ethereum ETFs that are having a moment, but ethereum overall. From a wave of ethereum treasury companies like SharpLink and BitMine popping up to Cathie Wood’s Ark Invest shifting its portfolio to increase exposure to ethereum and the asset itself hitting price levels it hasn’t seen in many months, it’s been a good run for the asset, and it doesn’t seem to be slowing down.

Paul Vigna’s “The Almightier” asks the question: how did the pursuit of wealth evolve from being the root of all evil to not just a virtue, but the central incentive of our entire culture? He sat down with Sherwood News to discuss why Western ideas about money are outdated and if there’s any societal benefit to crypto.

Read our first Talk Your Book feature.

Tariffs cost GM a reported $1.1 billion last quarter.

Advertiser's disclosures:

² The special unit offering is one share of convertible preferred stock (convertible into Nasdaq freely tradable common stock at any time) and one warrant to purchase an additional share of Nasdaq tradable common stock at a fixed price exercisable at any time for three years. Minimum investment is $675 (193 units). See prospectus for further details. 

³  A plan to file for FDA approval does not mean that the filing will occur. In addition, a filing for FDA approval is no guarantee of an actual FDA approval.

⁴ The minimum investment is $675 (193 units).This is a paid advertisement for HeartSciences’ Regulation A+ offering of Series D Convertible Preferred Stock and a Warrant. Please read the offering circular and related risks at HeartSciences website. Before making any investment, you are urged to read the prospectus carefully for a more complete understanding of the issuer and the offering. 

The securities offered by HeartSciences are highly speculative. Investing in these securities involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Investors must understand that such investment could be illiquid for an indefinite period of time. There is no existing public trading market for the Series D Convertible Preferred Stock. HeartScience does not intend to apply for listing of the Series D Convertible Preferred Stock or the common stock purchase warrants on a national securities exchange or quoted on an over the counter market.